Genmab — Januar 2025
-
Novo Nordisk leverede gode data på Amycretin mod fedme. DeepSeek sendte Nvidia ned - hvad skal der ske nu? Hør også om skuffede Genmab-investorer, de kommende regnskaber og meget mere i afsnit 259 af Investeringspodcasten. https://proinvestor.com/boards/124464
-
-
Det var igen, som i går, nogle enkelte rigtig store handler, der både øgede omsætningen mere end resten af dagens handler. 770K - 2Mio - 1Mio stk Adr blev handlet i den sidste time Dk var åben. Hele dagens handel blev næsten som i går: 5.347K + ca 7K i efterhandlen. Det var så efter den sidste store handel, at kursen steg til ca. slutkursen.
-
Roche: Columvi 172m CHF i 2024.
-
56m i Q4.
-
Sanofi: Sarclisa Q4 €130m (+26,2%), FY €471m (+23,6%)
-
Genmab's SWOT analysis: antibody specialist's stock faces post-Darzalex challenge - https://www.investing.com/news/swot-analysis/genmabs-swot-analysis-antibody-specialists-stock-faces-postdarzalex-challenge-93CH-3838074
-
Kort video:
Kinesisk chatbot, Nvidia, Tesla, Novo og Genmab https://proinvestor.com/boards/124479
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind